IN2014DN09554A - - Google Patents
Info
- Publication number
- IN2014DN09554A IN2014DN09554A IN9554DEN2014A IN2014DN09554A IN 2014DN09554 A IN2014DN09554 A IN 2014DN09554A IN 9554DEN2014 A IN9554DEN2014 A IN 9554DEN2014A IN 2014DN09554 A IN2014DN09554 A IN 2014DN09554A
- Authority
- IN
- India
- Prior art keywords
- cyclohexyl
- pharmaceutical compositions
- relates
- present
- diabetes
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- HPGJSAAUJGAMLV-UHFFFAOYSA-N 2-[[2-[[cyclohexyl-(4-propoxycyclohexyl)carbamoyl]amino]-1,3-thiazol-5-yl]sulfanyl]acetic acid Chemical compound C1CC(OCCC)CCC1N(C(=O)NC=1SC(SCC(O)=O)=CN=1)C1CCCCC1 HPGJSAAUJGAMLV-UHFFFAOYSA-N 0.000 abstract 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 abstract 1
- 108010011459 Exenatide Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 229940127003 anti-diabetic drug Drugs 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 229960001519 exenatide Drugs 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 abstract 1
- 229960004034 sitagliptin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to pharmaceutical compositions comprising {2- [3- cyclohexyl -3 (trans- 4- propoxy- cyclohexyl)- ureido]- thiazol- 5- ylsulfanyl}- acetic acid (FRI- 1) in combination with an anti- diabetic drug selected from the group consisting of metformin, sitagliptin or exenatide. The present invention also relates to the use of the pharmaceutical compositions in restoring insulin sensitivity and treating type II diabetes, including reducing body weight in subjects undergoing type II diabetes treatment.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648110P | 2012-05-17 | 2012-05-17 | |
| PCT/US2013/041076 WO2013173417A2 (en) | 2012-05-17 | 2013-05-15 | Glucokinase activator compositions for the treatment of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09554A true IN2014DN09554A (en) | 2015-07-17 |
Family
ID=48576527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9554DEN2014 IN2014DN09554A (en) | 2012-05-17 | 2013-05-15 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10004782B2 (en) |
| EP (1) | EP2849776B1 (en) |
| JP (1) | JP6234443B2 (en) |
| KR (2) | KR102371364B1 (en) |
| CN (2) | CN118453592A (en) |
| AU (2) | AU2013262895A1 (en) |
| BR (1) | BR112014028622A2 (en) |
| CA (1) | CA2872021C (en) |
| EA (1) | EA201492109A1 (en) |
| ES (1) | ES2878001T3 (en) |
| HK (1) | HK1202458A1 (en) |
| IL (1) | IL235484A0 (en) |
| IN (1) | IN2014DN09554A (en) |
| MX (1) | MX360304B (en) |
| SG (2) | SG11201406987UA (en) |
| WO (1) | WO2013173417A2 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101878252B1 (en) | 2010-05-26 | 2018-07-13 | 브이티브이 테라퓨틱스 엘엘씨 | Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator |
| IN2014DN09554A (en) | 2012-05-17 | 2015-07-17 | Transtech Pharma Llc | |
| KR102408480B1 (en) | 2018-05-30 | 2022-06-10 | 이삼구 | Composition for treating diabetic disease |
| US20210214312A1 (en) * | 2018-05-31 | 2021-07-15 | Hua Medicine (Shanghai) Ltd. | Pharmaceutical combination, composition and formulation containing glucokinase activator and a-glucosidase inhibitor, prepraration methods therefor and uses thereof |
| EP4487909A3 (en) * | 2018-06-12 | 2025-03-19 | vTv Therapeutics LLC | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| US11872221B2 (en) | 2020-01-31 | 2024-01-16 | Hua Medicine (Shanghai) Ltd. | Treating untreated or treatment-resistant diabetes with glucokinase activator |
| WO2021151251A1 (en) * | 2020-01-31 | 2021-08-05 | Hua Medicine (Shanghai) Ltd. | Treating treatment-resistant diabetes with glucokinase activator |
| WO2021167840A1 (en) | 2020-02-18 | 2021-08-26 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| CA3185834A1 (en) * | 2020-06-04 | 2021-12-09 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with hepatic impairment |
| WO2021243645A1 (en) * | 2020-06-04 | 2021-12-09 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with renal impairment |
| US11857536B2 (en) | 2020-06-04 | 2024-01-02 | Hua Medicine (Shanghai) Ltd. | Glucokinase activator for treating diabetes with renal impairment |
| CN116056760A (en) * | 2020-06-08 | 2023-05-02 | 维特卫治疗有限责任公司 | Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
| KR20230048502A (en) * | 2020-06-08 | 2023-04-11 | 브이티브이 테라퓨틱스 엘엘씨 | Salt or co-crystal of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
| CN115350268B (en) * | 2022-08-24 | 2025-02-11 | 深圳青澜生物技术有限公司 | A preparation for treating diabetes, microneedle and preparation process thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT323195B (en) | 1973-03-16 | 1975-06-25 | Hurka Wilhelm | PROCESS FOR PREPARING NEW SALT FROM BIGUANIDS |
| FR2243684B1 (en) | 1973-09-19 | 1977-01-28 | Semb | |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| US6794412B1 (en) * | 1999-03-11 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin |
| US6660716B1 (en) * | 1999-06-21 | 2003-12-09 | Eli Lilly And Company | Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagon-like peptide-1 and agonists thereof |
| US6294546B1 (en) * | 1999-08-30 | 2001-09-25 | The Broad Of Trustees Of The Leland Stanford Junior University | Uses of diterpenoid triepoxides as an anti-proliferative agent |
| US6608038B2 (en) * | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
| BR0312023A (en) | 2002-06-27 | 2005-03-22 | Novo Nordisk As | Compound, glucose kinase activating compound, method for preventing hypoglycemia, use of a compound, and pharmaceutical composition |
| JP4432901B2 (en) | 2003-02-26 | 2010-03-17 | 萬有製薬株式会社 | Heteroarylcarbamoylbenzene derivatives |
| KR20060052650A (en) | 2003-07-14 | 2006-05-19 | 소니 가부시끼 가이샤 | Information provision method |
| AU2003269484A1 (en) | 2003-09-11 | 2005-03-29 | Biocon Limited | Salt of atorvastatin with metformin |
| CN1910166B (en) * | 2004-01-06 | 2012-01-04 | 诺和诺德公司 | Heteroaryl ureas and their use as glucokinase activators |
| PL1723128T3 (en) | 2004-01-06 | 2013-04-30 | Novo Nordisk As | Heteroaryl-ureas and their use as glucokinase activators |
| WO2005123132A2 (en) * | 2004-06-17 | 2005-12-29 | Novo Nordisk A/S | Use of liver-selective glucokinase activators |
| US20060246141A1 (en) | 2005-04-12 | 2006-11-02 | Elan Pharma International, Limited | Nanoparticulate lipase inhibitor formulations |
| US20100028439A1 (en) | 2005-05-23 | 2010-02-04 | Elan Pharma International Limited | Nanoparticulate stabilized anti-hypertensive compositions |
| CN101258137A (en) * | 2005-07-08 | 2008-09-03 | 诺沃-诺迪斯克有限公司 | Dicycloalkylurea Glucokinase Activator |
| WO2007006761A1 (en) | 2005-07-08 | 2007-01-18 | Novo Nordisk A/S | Dicycloalkylcarbamoyl ureas as glucokinase activators |
| US7582769B2 (en) * | 2005-07-08 | 2009-09-01 | Novo Nordisk A/S | Dicycloalkyl urea glucokinase activators |
| JP4960355B2 (en) | 2005-07-14 | 2012-06-27 | ノボ・ノルデイスク・エー／エス | Urea-type glucokinase activator |
| JP5419706B2 (en) | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | Glucokinase activator |
| US8138185B2 (en) | 2007-01-09 | 2012-03-20 | Novo Nordisk A/S | Urea glucokinase activators |
| NZ589084A (en) | 2008-05-16 | 2012-06-29 | Takeda San Diego Inc | Glucokinase activators |
| JP5731196B2 (en) | 2008-07-22 | 2015-06-10 | 株式会社クレハ | Process for producing polyarylene sulfide having a reduced content of terminal halogen groups |
| WO2010107610A1 (en) * | 2009-03-17 | 2010-09-23 | Merck Sharp & Dohme Corp. | Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds |
| JP5077786B2 (en) | 2009-04-16 | 2012-11-21 | 大正製薬株式会社 | Concomitant medication |
| KR101190957B1 (en) | 2009-08-25 | 2012-10-15 | 한올바이오파마주식회사 | Metformin caffeic acid salt, preparation thereof, pharmaceutical composition comprising the same and combined formulation comprising the same |
| KR101878252B1 (en) * | 2010-05-26 | 2018-07-13 | 브이티브이 테라퓨틱스 엘엘씨 | Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator |
| EP2392575A1 (en) * | 2010-06-04 | 2011-12-07 | LEK Pharmaceuticals d.d. | A novel synthetic approach to ß-aminobutyryl substituted compounds |
| IN2014DN09554A (en) * | 2012-05-17 | 2015-07-17 | Transtech Pharma Llc | |
| KR20150123838A (en) | 2013-03-04 | 2015-11-04 | 브이티브이 테라퓨틱스 엘엘씨 | Stable glucokinase activator compositions |
| CA2903440C (en) | 2013-03-04 | 2021-04-13 | Vtv Therapeutics Llc | Solid compositions comprising a glucokinase activator and methods of making and using the same |
-
2013
- 2013-05-15 IN IN9554DEN2014 patent/IN2014DN09554A/en unknown
- 2013-05-15 SG SG11201406987UA patent/SG11201406987UA/en unknown
- 2013-05-15 HK HK15103235.2A patent/HK1202458A1/en unknown
- 2013-05-15 JP JP2015512779A patent/JP6234443B2/en active Active
- 2013-05-15 SG SG10201609644UA patent/SG10201609644UA/en unknown
- 2013-05-15 KR KR1020217006420A patent/KR102371364B1/en active Active
- 2013-05-15 CN CN202410499223.0A patent/CN118453592A/en active Pending
- 2013-05-15 EA EA201492109A patent/EA201492109A1/en unknown
- 2013-05-15 KR KR1020147035545A patent/KR20150013838A/en not_active Ceased
- 2013-05-15 AU AU2013262895A patent/AU2013262895A1/en not_active Abandoned
- 2013-05-15 MX MX2014013105A patent/MX360304B/en active IP Right Grant
- 2013-05-15 BR BR112014028622A patent/BR112014028622A2/en not_active Application Discontinuation
- 2013-05-15 CA CA2872021A patent/CA2872021C/en active Active
- 2013-05-15 CN CN201380024802.XA patent/CN104349790A/en active Pending
- 2013-05-15 WO PCT/US2013/041076 patent/WO2013173417A2/en not_active Ceased
- 2013-05-15 ES ES13726933T patent/ES2878001T3/en active Active
- 2013-05-15 EP EP13726933.8A patent/EP2849776B1/en active Active
- 2013-11-05 US US14/071,976 patent/US10004782B2/en active Active
-
2014
- 2014-11-03 IL IL235484A patent/IL235484A0/en unknown
-
2017
- 2017-06-07 AU AU2017203835A patent/AU2017203835B2/en active Active
-
2018
- 2018-05-18 US US15/983,249 patent/US10588943B2/en active Active
-
2020
- 2020-01-16 US US16/744,956 patent/US10980861B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210027547A (en) | 2021-03-10 |
| MX360304B (en) | 2018-10-29 |
| AU2013262895A1 (en) | 2014-11-13 |
| ES2878001T3 (en) | 2021-11-18 |
| US10004782B2 (en) | 2018-06-26 |
| SG11201406987UA (en) | 2014-12-30 |
| KR102371364B1 (en) | 2022-03-07 |
| AU2017203835B2 (en) | 2018-11-22 |
| IL235484A0 (en) | 2014-12-31 |
| JP6234443B2 (en) | 2017-11-22 |
| EP2849776A2 (en) | 2015-03-25 |
| CN118453592A (en) | 2024-08-09 |
| BR112014028622A2 (en) | 2017-06-27 |
| MX2014013105A (en) | 2015-04-08 |
| EP2849776B1 (en) | 2021-04-21 |
| US20140066372A1 (en) | 2014-03-06 |
| AU2017203835A1 (en) | 2017-06-22 |
| SG10201609644UA (en) | 2017-01-27 |
| EA201492109A1 (en) | 2015-07-30 |
| US10980861B2 (en) | 2021-04-20 |
| JP2015517525A (en) | 2015-06-22 |
| CA2872021A1 (en) | 2013-11-21 |
| CA2872021C (en) | 2022-08-16 |
| WO2013173417A3 (en) | 2014-02-20 |
| US10588943B2 (en) | 2020-03-17 |
| HK1202458A1 (en) | 2015-10-02 |
| US20200138909A1 (en) | 2020-05-07 |
| CN104349790A (en) | 2015-02-11 |
| US20180311314A1 (en) | 2018-11-01 |
| KR20150013838A (en) | 2015-02-05 |
| WO2013173417A2 (en) | 2013-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN09554A (en) | ||
| BR112013029256A2 (en) | "Pharmaceutical combinations for use in the treatment of patients with type 2 diabetes, treatment method, and uses of lixisenatide and metformin." | |
| IN2014KN02830A (en) | ||
| PH12015502042A1 (en) | Use of linagliptin in cardio-and renoprotective antidiabetic therapy | |
| EA201491934A1 (en) | GLUCAGON-LIKE PEPTIDE-2 ANALOGES (GLP-2) | |
| BR112015007685A2 (en) | exendin-4 derivatives as double glp1 / glucagon agonists | |
| BR112015013809A2 (en) | exendin-4 derivatives as glp1 / gip double agonists or glp1 / gip / lucagon trigonals, their use and pharmaceutical composition | |
| EA201590058A1 (en) | ANALOGUE GLUACAGONA | |
| CL2015001241A1 (en) | Use of interleukin 2 (il-2) to treat inflammatory or autoimmune-related disorders (div. Sol. No. 2608-13) | |
| CY1117603T1 (en) | LIXISENATIDE AS AN ADDITION TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES | |
| JP2011241213A5 (en) | ||
| MX354705B (en) | Novel glucagon analogues. | |
| WO2015106269A8 (en) | Rapid action insulin formulations and pharmaceutical delivery systems | |
| BR112014016810A2 (en) | compositions and methods for treating metabolic disorders | |
| UA113849C2 (en) | THE APPLICATION OF SIGMA LIGANDS IN TYPE 2 PATIENTS WITH PAIN | |
| BR112013029062A2 (en) | lixisenatide and metformin for the treatment of type 2 diabetes | |
| MX2013002244A (en) | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2. | |
| EA201201617A1 (en) | APPLICATION OF METMORPHINE IN COMBINATION WITH GLUCOKINASE ACTIVATOR AND COMPOSITIONS CONTAINING METMORPHIN AND GLUCOKINASE ACTIVATOR | |
| SA519401933B1 (en) | Insulin containing pharmaceutical compositions | |
| MY165122A (en) | Dipeptidyl peptidase-iv (dppiv) inhibitory peptide compound, composition containing the same, and production method for the same | |
| MX2016007989A (en) | Oxindole derivatives, preparation thereof and therapeutic use in the treatment of ampk-related diseases. | |
| TR201008226A2 (en) | An inhalation device containing capsules. | |
| MX2019003725A (en) | Metformin glycinate, pharmaceutical compositions comprising the same, and methods of using the same. | |
| IN2013MU03847A (en) | ||
| MX2015008555A (en) | Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders. |